172 related articles for article (PubMed ID: 30976029)
1. CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation.
Tarkiainen M; Sipola P; Jalanko M; Heliö T; Jääskeläinen P; Kivelä K; Laine M; Lauerma K; Kuusisto J
Sci Rep; 2019 Apr; 9(1):5960. PubMed ID: 30976029
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.
Tarkiainen M; Sipola P; Jalanko M; Heliö T; Laine M; Järvinen V; Häyrinen K; Lauerma K; Kuusisto J
J Cardiovasc Magn Reson; 2016 Jun; 18(1):33. PubMed ID: 27259862
[TBL] [Abstract][Full Text] [Related]
3. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
[TBL] [Abstract][Full Text] [Related]
4. Assessment of myocardial oxygenation, strain, and diastology in MYBPC3-related hypertrophic cardiomyopathy: a cardiovascular magnetic resonance and echocardiography study.
Grover S; Lloyd R; Perry R; Lou PW; Haan E; Yeates L; Woodman R; Atherton JJ; Semsarian C; Selvanayagam JB
Eur Heart J Cardiovasc Imaging; 2019 Aug; 20(8):932-938. PubMed ID: 30668650
[TBL] [Abstract][Full Text] [Related]
5. Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy.
Reant P; Captur G; Mirabel M; Nasis A; M Sado D; Maestrini V; Castelletti S; Manisty C; Herrey AS; Syrris P; Tome-Esteban M; Jenkins S; Elliott PM; McKenna WJ; Moon JC
J Cardiovasc Magn Reson; 2015 Jul; 17(1):64. PubMed ID: 26219660
[TBL] [Abstract][Full Text] [Related]
6. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
Farhad H; Seidelmann SB; Vigneault D; Abbasi SA; Yang E; Day SM; Colan SD; Russell MW; Towbin J; Sherrid MV; Canter CE; Shi L; Jerosch-Herold M; Bluemke DA; Ho C; Neilan TG
J Cardiovasc Magn Reson; 2017 Dec; 19(1):107. PubMed ID: 29284499
[TBL] [Abstract][Full Text] [Related]
7. Hypertrophic cardiomyopathy in myosin-binding protein C (
Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
[TBL] [Abstract][Full Text] [Related]
8. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy.
Valente AM; Lakdawala NK; Powell AJ; Evans SP; Cirino AL; Orav EJ; MacRae CA; Colan SD; Ho CY
Circ Cardiovasc Genet; 2013 Jun; 6(3):230-7. PubMed ID: 23690394
[TBL] [Abstract][Full Text] [Related]
9. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
[TBL] [Abstract][Full Text] [Related]
10. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation.
Sipola P; Magga J; Husso M; Jääskeläinen P; Peuhkurinen K; Kuusisto J
Eur Radiol; 2011 Jul; 21(7):1383-9. PubMed ID: 21274714
[TBL] [Abstract][Full Text] [Related]
11. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
[TBL] [Abstract][Full Text] [Related]
12. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations.
Jalanko M; Heliö T; Mustonen P; Kokkonen J; Huhtala H; Laine M; Jääskeläinen P; Tarkiainen M; Lauerma K; Sipola P; Laakso M; Kuusisto J; Nikus K
J Electrocardiol; 2018; 51(6):983-989. PubMed ID: 30497761
[TBL] [Abstract][Full Text] [Related]
13. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.
Ho CY; Day SM; Colan SD; Russell MW; Towbin JA; Sherrid MV; Canter CE; Jefferies JL; Murphy AM; Cirino AL; Abraham TP; Taylor M; Mestroni L; Bluemke DA; Jarolim P; Shi L; Sleeper LA; Seidman CE; Orav EJ;
JAMA Cardiol; 2017 Apr; 2(4):419-428. PubMed ID: 28241245
[TBL] [Abstract][Full Text] [Related]
14. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations.
Pöyhönen P; Hiippala A; Ollila L; Kaasalainen T; Hänninen H; Heliö T; Tallila J; Vasilescu C; Kivistö S; Ojala T; Holmström M
J Cardiovasc Magn Reson; 2015 Oct; 17():89. PubMed ID: 26496977
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular hypertrophy reclassification and death: application of the Recommendation of the American Society of Echocardiography/European Association of Echocardiography.
Barbieri A; Bursi F; Mantovani F; Valenti C; Quaglia M; Berti E; Marino M; Modena MG
Eur Heart J Cardiovasc Imaging; 2012 Jan; 13(1):109-17. PubMed ID: 21979990
[TBL] [Abstract][Full Text] [Related]
17. Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers.
Hughes RK; Camaioni C; Augusto JB; Knott K; Quinn E; Captur G; Seraphim A; Joy G; Syrris P; Elliott PM; Mohiddin S; Kellman P; Xue H; Lopes LR; Moon JC
J Am Heart Assoc; 2021 Aug; 10(15):e020227. PubMed ID: 34310159
[TBL] [Abstract][Full Text] [Related]
18. Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population.
Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Nieminen MS; Laakso M; Kuusisto J; ; Kervinen H; Mustonen J; Juvonen J; Niemi M; Uusimaa P; Huttunen M; Kotila M; Pietilä M
Ann Med; 2013 Feb; 45(1):85-90. PubMed ID: 22462493
[TBL] [Abstract][Full Text] [Related]
19. Right ventricular myocardial diastolic dysfunction in different kinds of cardiac hypertrophy: analysis by pulsed Doppler tissue imaging.
Galderisi M; Severino S; Caso P; Cicala S; Petrocelli A; De Simone L; Mininni N; de Divitiis O
Ital Heart J; 2001 Dec; 2(12):912-20. PubMed ID: 11838339
[TBL] [Abstract][Full Text] [Related]
20. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
Ho CY; Lakdawala NK; Cirino AL; Lipshultz SE; Sparks E; Abbasi SA; Kwong RY; Antman EM; Semsarian C; González A; López B; Diez J; Orav EJ; Colan SD; Seidman CE
JACC Heart Fail; 2015 Feb; 3(2):180-8. PubMed ID: 25543971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
